Hangzhou Alltest Biotech Co., Ltd. (SHA:688606)

Hangzhou Alltest Biotech Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	984.4	920.38	1,318	1,982	2,179	285.64
Trading Asset Securities	1,474	1,657	1,471	1,833	780.2	415
Cash & Short-Term Investments	2,459	2,578	2,789	3,815	2,960	700.64
Cash Growth	-7.68%	-7.57%	-26.89%	28.90%	322.40%	459.38%
Accounts Receivable	166.1	125.12	100.87	138.66	208.2	163.44
Other Receivables	5.99	6.67	8.18	10.35	67.4	2.29
Receivables	172.09	131.79	109.05	149.02	275.6	165.72
Inventory	180.71	160.32	188.59	193.66	383.84	123.73
Prepaid Expenses	-	0.71	11.65	2.15	8.19	-
Other Current Assets	116.21	94.75	63.24	29.63	41.03	35.09
Total Current Assets	2,928	2,965	3,161	4,189	3,668	1,025
Property, Plant & Equipment	950.52	903.44	759.8	317.14	223.62	66.81
Long-Term Investments	117.22	128.67	22.95	12.2	54.32	-
Other Intangible Assets	138.27	104.97	110.43	93.03	28.12	28.79
Long-Term Deferred Tax Assets	22.99	22.2	30.18	46.44	3.82	4.07
Long-Term Deferred Charges	9.65	10.35	15.72	17.88	5.66	2.15
Other Long-Term Assets	75.74	51.1	15.53	18.96	24.62	24.11
Total Assets	4,242	4,186	4,116	4,695	4,008	1,151
Accounts Payable	67.44	104.8	77.61	171.17	360.65	62
Accrued Expenses	19.19	32.41	33.16	73.51	44.61	32.6
Current Portion of Leases	0.29	2.34	16.26	8.32	20.06	-
Current Income Taxes Payable	92.17	86.43	73.96	73.26	61.71	50.31
Current Unearned Revenue	41.14	40.84	41.62	147.2	226.27	33.38
Other Current Liabilities	109.31	32.37	31.56	37.29	0.91	0.15
Total Current Liabilities	329.54	299.19	274.16	510.75	714.2	178.45
Long-Term Leases	7.96	1.76	7.66	13.44	17.3	-
Long-Term Unearned Revenue	3.17	1.64	2.68	-	-	-
Long-Term Deferred Tax Liabilities	0.01	0.01	-	-	3.2	-
Total Liabilities	340.68	302.6	284.5	524.2	734.71	178.45
Common Stock	79.28	79.28	79.28	53.9	53.9	40.4
Additional Paid-In Capital	1,697	1,708	1,713	1,744	1,733	102.8
Retained Earnings	2,172	2,177	2,107	2,455	1,487	829.33
Treasury Stock	-77.9	-113.01	-103.4	-115.56	-	-
Comprehensive Income & Other	31.89	32.5	30.75	28.39	0.26	0.13
Total Common Equity	3,902	3,884	3,827	4,166	3,274	972.66
Minority Interest	-0.43	-0.22	4.31	4.4	-	-
Shareholders' Equity	3,901	3,883	3,832	4,171	3,274	972.66
Total Liabilities & Equity	4,242	4,186	4,116	4,695	4,008	1,151
Total Debt	8.25	4.1	23.91	21.77	37.36	-
Net Cash (Debt)	2,450	2,574	2,765	3,793	2,922	700.64
Net Cash Growth	-7.69%	-6.92%	-27.10%	29.80%	317.07%	459.38%
Net Cash Per Share	30.92	32.50	34.91	47.86	39.07	11.72
Filing Date Shares Outstanding	78.31	77.87	77.53	78.24	79.78	59.8
Total Common Shares Outstanding	78.31	77.87	78.16	78.24	79.78	59.8
Working Capital	2,598	2,666	2,887	3,678	2,954	846.73
Book Value Per Share	49.83	49.87	48.97	53.25	41.03	16.27
Tangible Book Value	3,764	3,779	3,717	4,073	3,246	943.87
Tangible Book Value Per Share	48.06	48.53	47.56	52.06	40.68	15.78
Buildings	-	403.78	194.44	198.85	58.13	46.61
Machinery	-	117.42	113.61	91.69	58.93	19.04
Construction In Progress	-	459.92	488.25	42.3	82.37	11.62

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.